Biomarin Pharmaceutical (BMRN) Current Taxes (2010 - 2019)

Biomarin Pharmaceutical has disclosed Current Taxes across 10 years of filings, most recently posting $11.4 million for Q1 2019.

• Quarterly Current Taxes rose 11.06% year-over-year to $11.4 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $11.4 million (up 11.06% YoY) and the FY2018 annual result came in at $7.8 million, down 20.07% from the prior year.
• Current Taxes improved to $11.4 million in Q1 2019, from $7.8 million in the prior quarter.
• Over five years, Current Taxes peaked at $11.4 million in Q1 2019 and troughed at $2.7 million in Q2 2018.
• A 5-year average of $8.1 million and a median of $8.6 million in 2017 frame the typical range for Current Taxes.
• Annual changes were most pronounced in 2015 — Current Taxes surged 132.38% — and 2018, when it slumped 69.13%.
• Tracing BMRN's Current Taxes over 5 years: stood at $6.4 million in 2015, then jumped by 46.07% to $9.3 million in 2016, then grew by 4.56% to $9.7 million in 2017, then retreated by 20.07% to $7.8 million in 2018, then jumped by 45.81% to $11.4 million in 2019.
• Business Quant data shows BMRN's Current Taxes at $11.4 million in Q1 2019, $7.8 million in Q4 2018, and $8.6 million in Q3 2018.